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Background: Allergic	diseases	 (eczema,	wheeze	and	 rhinitis)	 in	children	often	pre‐
sent	as	heterogeneous	phenotypes.	Understanding	genetic	associations	of	specific	












before	 and	 after	 Bonferroni	 correction.	 Results	 were	 replicated	 in	 Manchester	
Asthma	and	Allergy	Study	(MAAS)	(n	=	896)	and	pooled	in	a	meta‐analysis.








Conclusions and clinical relevance: We	have	shown	complex,	but	distinct	patterns	
of	 genetic	 associations	 with	 LCADs,	 suggesting	 that	 heterogeneous	 mechanisms	
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1  | INTRODUC TION
Although	asthma,	eczema	(atopic	dermatitis)	and	allergic	rhinitis	(AR)	
are	 diagnosed	 clinically	 as	 distinct	 conditions,	 their	 co‐occurrence	






























including	73	novel	variants,	and	went	on	 to	 link	 the	pathophysiol‐












Avon	 Longitudinal	 Study	 of	 Parents	 and	Children	 is	 a	 population‐




and	 local	 research	ethics	 committees.	The	 study	website	 contains	








2.2 | Latent classes of allergic diseases (LCADs)
Eight	LCADs	were	previously	identified	using	a	latent	disease	profile	
model	in	a	Bayesian	machine	learning	modelling	framework	applied	
to	 longitudinal	 individual	 reports	 of	 eczema,	 wheezing	 and	 rhini‐
tis	 collected	at	multiple	 time	points	between	ages	1	and	11	years	
using	 joint	 ALSPAC	 and	 MAAS	 data8,14:	 “No	 disease”,	 “Atopic	
march,”	 “Persistent	 eczema	 and	wheeze,”	 “Persistent	 eczema	with	
later‐onset	 rhinitis”,	 “Persistent	 wheeze	 with	 later‐onset	 rhinitis,”	






In	 ALSPAC,	 we	 used	 the	 Illumina	 HumanHap550	 quad	 chip	 and	
imputed	 against	 the	Dec	 2013	Version	 1	 Phase	 3	 release	 of	 1000	
Genomes	reference	haplotypes15	using	IMPUTE2.16	Participants	with	




K E Y W O R D S
asthma,	atopic	dermatitis,	Avon	Longitudinal	Study	of	Parents	and	Children,	eczema,	genetics,	
rhinitis















fect	 sizes	 observed	 in	 Ref.	 9.	 The	 standardized	 PRS	 represented	 a	
per	1‐standard	deviation	increase	in	the	weighted	risk	score	(details	
in	Supplemental	Material).	Individual	SNPs	were	also	analysed	sepa‐
rately,	where	each	SNP	was	coded	as	 the	dosage	of	 the	 risk	 allele.	
Following	 investigation	 of	 individual	 SNPs,	 a	 modified	 PRS,	 which	



















In	 the	 single	 SNP	 analysis,	 a	 Bonferroni‐corrected	 P‐value 
threshold	was	calculated	 (P	=	 .05/135	=	3.7	×	10−4)	 to	 control	 for	
type	 1	 error.	 For	 six	 SNPs	 reported	 as	 disease‐specific	 in	 GWAS	
(rs61816761,	 rs921650,	 rs115288876,	 rs12470864,	 rs6594499	
and	rs61839660),9	a	 less	stringent	p‐value	threshold	of	8.3	×	10−3 
(0.05/6)	was	also	used.
To	 assess	 the	 level	 of	 power	 in	 the	 analysis	 of	 ALSPAC	 data,	
power	calculations	were	conducted	for	associations	with	individual	
phenotypes	(details	in	the	Supplemental	Material	and	Table	S2).
















cial	 class	 (P	 =	 3.54	×	10−29)	 and	 lower	maternal	 educational	 level	
(P	=	1.31	×	10−62)	in	ALSPAC,	as	seen	before.20	Marginal	evidence	
for	lower	social	class	among	the	excluded	individual	was	observed	

















with	 LCADs.	 Two	 SNPs,	 rs61816761	 (a	 protein‐truncating	 variant	
in FLG)	 and	 rs921650	 (within	an	 intron	of	GSDMB),	 showed	strong	
evidence	 for	differential	 association	between	 the	LCADs	 (P‐values	
0.002	 and	 1.42	 ×	 10−5,	 respectively,	 excluding	 “No	 disease”	 class)	
(Table	S5	and	Figures	2	and	3).	Pairwise	 tests	provide	 further	evi‐
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Characteristics
Study sampled
Excluded sample (no 




acteristic (%) Total N
N with char‐
acteristic (%) Total N
ALSPAC
Gender	(male) 3244	(51.1) 6345 4375	(51.6) 8479 0.575
Lower	combined	
social	classa
2617	(43.9) 5957 3017	(54.4) 5547 3.54E‐29
Lower	maternal	edu‐
cational	levelb
3577	(57.5) 6220 4466	(71.8) 6218 1.31E‐62
Allergic	diseases	latent	classese
No	Disease 3175	(50.0) 6345 1150	(49.8) 2309 (Reference)












Transient	wheeze 534	(8.4) 195	(8.4) 0.939
Eczema	only 948	(15.0) 323	(14.0) 0.394
Rhinitis	only 677	(10.7) 250	(10.8) 0.820
MAAS
Gender	(male) 482	(53.8) 896 186	(55.7) 287 0.305
Lower	combined	
social	classa
225	(36.9) 610 60	(43.2) 139 0.101
Lower	maternal	edu‐
cational	levelb
359	(55.3) 649 45	(57.7) 78 0.392
Allergic	diseases	latent	classese
No	Disease 322	(35.9) 896 87	(38.9) 223 (reference)












Transient	wheeze 65	(7.3) 15	(6.8) 0.644
Eczema	only 141	(15.7) 34	(15.3) 0.634










TA B L E  1  Characteristics	of	the	
study	populations	in	ALSPAC	and	MAAS	
cohorts
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A	modified	 PRS	 which	 excluded	 these	 two	 SNPs	 still	 showed	
strong	 evidence	 for	 differential	 association	 (heterogeneity	 P‐
value	=	9.6	×	10−12,	 Table	 S3;	 Figure	4),	 suggesting	 that	 there	 are	
additional	differential	 associations	 among	 the	SNPs	which	did	not	
meet	our	significance	threshold.
Four	 additional	 SNPs	 (rs11652139,	 rs479844,	 rs6990534	 and	








3.3 | Replication in MAAS and Pooled Estimates
3.3.1 | Standardized genetic scores (original and 
modified)
The	 associations	 between	 the	PRS	 and	 LCADs	 in	MAAS	were	 re‐
markably	similar	to	ALSPAC	(Table	S7	and	Figure	1).	 In	the	pooled	
F I G U R E  1  Forest	plot	of	the	associations	between	the	standardized	genetic	score	and	allergic	disease	latent	classes	in	ALSPAC	and	
MAAS	cohorts
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analysis,	 there	 was	 strong	 evidence	 for	 differential	 association	
across	LCADs	(excluding	the	baseline	class;	P‐value	=	3.27	×	10−14).	
To	 investigate	 the	 nature	 of	 these	 differences,	we	 compared	ORs	
and	 CIs	 across	 the	 seven	 classes.	 There	was	 evidence	 for	 a	 large	
effect	 on	 “Atopic	 march”	 (pooled	 RRR	 =	 1.99,	 95%	 CI	 1.74‐2.29),	
“Persistent	 eczema	 with	 late‐onset	 rhinitis”	 (1.51,	 1.35‐1.68),	
“Persistent	 wheeze	 with	 late‐onset	 rhinitis”	 (1.44,	 1.30‐1.60)	 and	
“Persistent	eczema	and	wheeze”	(1.39,	1.22‐1.60),	per	1‐SD	increase	
in	 the	 per‐risk‐allele	 standardized	 PRS	 compared	 to	 “No	 disease”.	
A	modest	 increased	 risk	was	observed	 for	 LCADs	affecting	 single	
organ/system:	 “Transient	wheeze”	 (1.11,	1.02‐1.21),	 “Eczema	only”	







F I G U R E  2  Forest	plot	of	the	associations	between	SNP	rs61816761[A]	near	Filaggrin	gene	and	allergic	disease	latent	classes	in	ALSPAC	
and	MAAS	cohorts





LCADs	 (excluding	 the	 baseline	 class)	 for	 SNPs	 rs61816761,	
rs921650	and	rs11652139	(pooled	heterogeneity	P‐values	≤	.006).	
To	investigate	the	nature	of	these	differences,	we	compared	ORs	
and	CIs	 across	 the	7	 LCADs.	There	was	 evidence	 for	 a	 large	 ef‐
fect	 on	 “Atopic	 march”	 (pooled	 RRR	 =	 3.01,	 95%CI	 1.79‐5.08),	
“Persistent	 eczema	 and	 wheeze”	 (1.87,	 1.01‐3.48),	 “Persistent	
eczema	 with	 late‐onset	 rhinitis”	 (2.30,	 1.45‐3.65)	 and	 “Eczema	
only”	 (1.63,	 1.15‐2.30),	 per	 increased	 A‐allele	 of	 rs61816761	 (a	
protein‐truncating	variant	 in	FLG)	 (Table	3;	Figure	2).	Little	or	no	
evidence	of	association	was	seen	for	other	LCADs.	We	found	evi‐
dence	 for	 a	 large	 effect	 on	 “Atopic	march”	 (pooled	 RRR	 =	 1.36,	
95%CI	 1.13‐1.65),	 “Persistent	 eczema	 and	 wheeze”	 (1.37,	
1.13‐1.66),	 “Persistent	 wheeze	 with	 late‐onset	 rhinitis”	 (1.36,	
1.18‐1.57)	and	“Transient	wheeze”	(1.24,	1.10‐1.40),	per	increased	
A‐allele	 of	 rs921650	 (within	 an	 intron	 of	GSDMB),	 compared	 to	
“No	disease”	(Table	3;	Figure	3).	Little	or	no	evidence	of	associa‐
tion	was	seen	for	other	LCADs.
F I G U R E  3  Forest	plot	of	the	associations	between	SNP	rs921650[A]	near	GSDMB	gene	and	allergic	disease	latent	classes	in	ALSPAC	and	
MAAS	cohorts
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The	pattern	of	associations	for	SNP	rs11652139	was	very	sim‐












ants	 for	 allergic	 diseases	 identified	 in	 a	 recent	GWAS9	 and	LCADs	





included	eczema,	with	 stronger	associations	 seen	 for	 those	classes	
with	comorbid	wheeze	and/or	rhinitis.	In	contrast,	the	strength	of	the	
F I G U R E  4  Forest	plot	of	the	associations	between	the	modified	standardized	genetic	score	(excluding	SNPs	rs61816761	and	rs921650)	
and	allergic	disease	latent	classes	in	ALSPAC	and	MAAS	cohorts
     |  9CLARK et AL.
association	for	GSDMB	locus	was	equal	for	all	LCADs	which	included	
wheeze,	with	no	 additional	 risk	 for	 comorbid	 eczema	 and/or	 rhini‐
tis.	An	 allergic	 disease	polygenic	 risk	 score	 (including	 all	 135	SNPs	
and	after	excluding	SNPs	rs61816761	and	rs921650)	showed	strong	
evidence	of	 heterogeneity	 across	 the	 LCADs,	 suggesting	 there	 are	
further	individual	SNPs	with	differential	association.
4.1 | rs61816761 (FLG)
rs61816761	 (also	 known	 as	R501X)	 has	 long	 been	 linked	with	 ec‐
zema.21	In	Ferreira's	GWAS,9	the	risk	allele	[A]	for	SNP	rs61816761,	
which	 is	 located	on	chromosome	1	 in	the	FLG	gene,	was	1.32‐fold	
more	 common	 in	 individuals	 experiencing	 eczema‐only	 symptoms	
Allergic diseases latent classes
ALSPAC‐MAAS pooled multinomial odds ratio 
(95% CI)
Stand. Score
Stand. Score excluding 























TA B L E  3  ALSPAC‐MAAS	pooled	estimates	of	the	associations	between	the	top	six	nominal	SNPs	(heterogeneity	p‐value	excluding	the	
baseline	“no	disease”	class	<	0.05)	and	allergic	diseases	latent	classes
SNP[RA]
ALSPAC‐MAAS pooled multinomial odds ratio (95% CI)
rs61816761[A] rs921650[A]
rs11652139[A] rs479844[G] rs6990534[A] rs5743618[C]Nearby Gene FLG GSDMB
Allergic	diseases	latent	classes
Atopic	March 3.01	(1.79,5.08) 1.36	(1.13,1.65) 1.47	(1.20,1.80) 1.12	(0.92,1.36) 1.33	(1.09,1.62) 1.31	(1.04,1.67)
Persistent	eczema	
and	wheeze








0.87	(0.47,1.62) 1.36	(1.18,1.57) 1.22	(1.05,1.42) 0.95	(0.82,1.10) 1.03(0.88,1.21) 1.13	(0.96,1.35)
Transient	wheeze 1.00	(0.60,1.66) 1.24	(1.10,1.40) 1.15	(1.02,1.31) 1.02	(0.90,1.16) 0.93	(0.81,1.07) 0.97	(0.84,	1.13)
Eczema	only 1.63	(1.15,2.30) 0.99	(0.90,1.09) 0.98	(0.88,1.08) 1.14	(1.03,1.26) 0.96	(0.86,1.07) 0.99	(0.89,	1.11)
Rhinitis	only 1.08	(0.69,1.68) 1.00	(0.90,1.12) 1.04	(0.93,1.17) 0.95	(0.85,1.06) 1.10	(0.98,1.24) 1.19	(1.04,	1.36)
P‐value	for	differen‐
tial	associationa 
0.006 1.71E‐05 0.006 0.044 0.055 0.138
P‐value	for	any	
associationb 
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compared	with	 individuals	experiencing	only	AR.	Similarly,	a	1.26‐







3.01).	 This	 is	 in	 line	with	 a	 recent	meta‐analysis	which	 found	 that	
the	two	FLG	mutations	combined	(R501X	and	FLG	2282del4)	were	
associated	with	Atopic	march.22
It	 is	 tempting	 to	 speculate	 that	 genotyping	 patients	 with	 ec‐
zema	for	FLG	mutations	could	help	to	identify	individuals	who	may	
benefit	from	interventions	targeted	at	prevention	of	progression	to	
the	atopic	march.23	However,	 the	difference	 in	odds	between	 the	
“Atopic	march”	versus	“Eczema	only”	classes	is	of	insufficient	mag‐
nitude	to	be	of	a	clinical	predictive	value.	It	is	also	important	to	note	









and	AR.	 In	 the	 present	 study,	we	 found	 evidence	 for	 a	 large	 ef‐
fect	 on	 all	 four	wheeze‐related	 classes	 per	 increased	 A‐allele	 of	
rs921650.	However,	unlike	for	associations	with	FLG	locus,	where	
we	 observed	 increasing	 odds	 for	 classes	 with	 comorbid	 wheeze	
and	 rhinitis	 (ORs	 from	1.87	 to	3.01)	when	compared	 to	 “Eczema	
only”	class	 (OR	1.63),	 for	associations	with	GSDMB	 locus,	we	did	





rs921650	 is	 located	within	 an	 intron	 of	GSDMB	 (gasdermin	B)	
gene	(also	known	as	GSDML),25,26	likely	affecting	the	expression	of	
genes	 in	 the	17q21	 locus.	 SNPs	 in	 the	17q21	 locus	have	been	as‐
sociated	 with	 childhood	 asthma,	 and	 there	 is	 evidence	 that	 com‐
mon	SNPs	 in	 this	 region	 are	 associated	with	 persistent	wheeze.27 
Results	of	our	analysis	 are	consistent	with	 this	evidence,	with	 the	
increased	risk	of	three	classes	characterized	by	wheeze	persistence	
(“Persistent	wheeze	with	late‐onset	rhinitis,”	“Persistent	eczema	and	





early‐life	wheeze	 in	 the	 absence	of	 other	 allergic	 symptoms	 (such	








4.3 | Interpretation of the Polygenic Risk Score 
(PRS)
We	report	strong	evidence	of	heterogeneity	of	associations	across	
the	 LCADs	 (pooled	 het.	P‐value	 =	 3.3	 ×	 10−14	 excluding	 “No	 dis‐
ease”	class).	The	strongest	association	was	seen	for	“Atopic	march”	
(pooled	 RRR	 1.99,	 1.74‐2.29).	 Our	 results	 suggest	 that	 although	
the	presence	of	multiple	 risk	alleles	 increases	the	risk	of	all	 latent	
classes,	 this	 is	 strongest	 for	 the	 “Atopic	march,”	 and	weakest	 for	
the	classes	characterized	by	the	presence	of	single	symptoms.	This	
may	indicate	that	the	greater	the	standardized	per‐allele	weighted	
PRS,	 the	 greater	 the	 likelihood	 of	 developing	multiple	 comorbidi‐
ties.	 After	 excluding	 SNPs	 rs61816761	 and	 rs921650,	 this	 effect	
was	 still	observed	 (pooled	het.	P‐value	=	1.1	×	10−12).	As	none	of	
these	 133	 individual	 SNPs	 showed	 good	 evidence	 for	 differential	







files	were	 identified	 in	MAAS	 and	ALSPAC,	 suggesting	 consistent	
patterns	across	 the	 two	populations.8	 Furthermore,	we	have	used	




ing	genetic	and/or	outcome	data)	 resulted	 in	a	 loss	of	participants	
from	 lower	 social	 class	 and	 maternal	 educational	 level.	 Selection	
bias	 can	 be	 introduced	 if	 the	 individuals	 from	 a	 lower	 social	 class	
had	missing	data	because	of	factors	related	to	the	outcome.	Issues	
such	as	 this	 can	 also	 impact	on	 the	generalizability	of	 the	 results.	
However,	 despite	 the	 loss	 of	 individuals	 from	 lower	 social	 class,	
there	was	still	a	good	representation	in	the	included	study	samples	
(43.9%	in	ALSPAC	and	36.9%	in	MAAS).
Avon	 Longitudinal	 Study	 of	 Parents	 and	 Children	 was	 part	 of	
the	 meta‐analysis	 by	 Ferreira	 et	 al	 that	 was	 used	 to	 identify	 the	
136	SNPs;	 this	 could	have	 led	 to	 some	overfitting	 in	our	ALSPAC	
analysis.	However,	 our	 sample	 only	makes	 up	 0.6%	of	 the	 sample	
used	by	Ferreira	et	al	and	our	main	analysis	focuses	on	the	compar‐
ison	between	case	(disease)	groups,	rather	than	the	comparison	of	









variants	 identified	 to	date	by	Ferreira	et	 al	play	 in	allergic	disease	
profiles	is	beneficial,	a	 limitation	of	the	Ferreira	approach	is	that	 it	
is	better	powered	to	detect	homogenous	as	opposed	to	heteroge‐





sizes	 increase,	 it	may	be	possible	to	undertake	such	 latent	disease	
profile	 analyses	 in	 a	 GWAS	 context	 with	 better	 power	 to	 detect	
novel	loci	with	heterogenous	effects.
4.5 | Conclusions
We	 found	 strong	 evidence	 for	 differential	 genetic	 associations	
across	 different	 developmental	 profiles	 of	 eczema,	 wheeze	 and	




included	 eczema,	 but	 with	 stronger	 associations	 for	 those	 with	
comorbid	 wheeze	 and/or	 rhinitis.	 The	 GSDMB	 locus	 in	 contrast	
was	 associated	 with	 all	 profiles	 which	 included	 wheeze	 (includ‐
ing	wheezing	up	to	age	5 years	with	remission	by	age	8 years),	but	
with	 no	 additional	 risk	 of	 comorbid	 conditions.	 This	 emphasizes	
the	 likely	 complex	 and	 heterogeneous	 mechanisms	 underlying	
within‐individual	disease	trajectories	and	demonstrates	the	need	
for	future	studies	to	take	account	of	the	complex	nature	of	these	
associations.	 Our	 analysis	 using	 a	 PRS	 also	 demonstrates	 that	
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